Evotec Completes Acquisition of Kinaxo Biotechnologies GmbH

Tuesday, 19. April 2011 07:33
Evotec AG /
Evotec Completes Acquisition of Kinaxo Biotechnologies GmbH
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

Hamburg, Germany - 19 April 2011: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) today announced that it has completed the acquisition of Kinaxo
Biotechnologies GmbH, a privately held drug discovery alliance company
supporting the development of targeted drugs. As a result of the transaction,
first announced on February 9, 2011, Kinaxo has become a wholly-owned subsidiary
of Evotec. It is intended to grow and fully integrate the Kinaxo site in Munich,
as Evotec Munich.

With the acquisition of Kinaxo, Evotec is expanding its drug discovery platform
with cutting-edge technologies. Furthermore, Evotec adds proprietary
technologies for drug response prediction as well as drug efficacy and safety
assessment, especially in the key indication area oncology. Kinaxo's
capabilities comprise a unique combination of innovative technologies improving
drug discovery and development across the entire pharma value chain. These
skills strengthen Evotec's position as the quality leader in drug discovery. The
synergies are expected to result in a much broader customer reach through
integration of the former Kinaxo service business into Evotec's performance
based drug discovery alliances.

With the completion of the acquisition the sellers of the shares in Kinaxo
Biotechnologies GmbH transferred 100% of their shares to Evotec AG. Therewith,
all Closing conditions have been successfully fulfilled. Evotec AG issues
2.597.400 shares from its authorized capital as part consideration for the
transaction. All Evotec shares issued are subject to certain lock-up provisions.
Following the registration of these shares at the trade register, Evotec's
issued share capital will be €118.193.132.

Dr Werner Lanthaler, Chief Executive Officer, Phone: +49.(0)40.56081-242,
werner.lanthaler@evotec.com

Forward-Looking Statements - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. Such forward-looking statements include, but are not limited to,
statements regarding our expectation that our current cash, cash equivalents,
investments, and operating revenues will be sufficient to fund our planned
activities beyond 2015; our financial outlook for 2011 and 2012, including
statements regarding our expected operating results and financing and financial
position, our belief that our cash situation should remain strong throughout
2011, and our expected liquidity at the end of 2011; our revised business model
providing a sound basis for long-term sustainable growth; the anticipated
advantages of our acquisitions and collaborations, including the expected
revenue contribution from our acquisition of Kinaxo Biotechnologies GmbH; our
expectations regarding the market for drug discovery alliances, including
anticipated growth of the pharmaceutical outsourcing drug discovery market and
the opportunities such growth will provide us, and our ability to take advantage
of such market developments; our goal to reach operating profitability and to
generate cash sustainable by 2012; our beliefs regarding the sufficiency of our
existing liquidity reserves; our capital-raising plans; the expected timing of
the effectiveness of our deregistration with the SEC; our expectations and
assumptions concerning regulatory, clinical, and business strategies; and the
progress of our clinical development programs and timing of the results of our
clinical trials, strategic collaborations, acquisitions, and management's plans,
objectives and strategies. These statements are neither promises nor guarantees,
but are subject to a variety of risks and uncertainties, many of which are
beyond our control, and which could cause actual results to differ materially
from those contemplated in these forward-looking statements. In particular, the
risks and uncertainties include, among other things: risks that we may be unable
to achieve the anticipated benefits of our revised business model or recognise
the results of our revised business model within expected timeframes; risks that
we will not achieve the anticipated benefits of our collaborations, partnerships
and acquisitions in the timeframes expected, or at all; risks that product
candidates may fail in the clinic or may not be successfully marketed or
manufactured; risks relating to our ability to advance the development of
product candidates currently in the pipeline or in clinical trials; our
inability to further identify, develop and achieve commercial success for new
products and technologies; the risk that competing products may be more
successful; our inability to interest potential partners in our technologies and
products; our inability to achieve commercial success for our products and
technologies; our inability to protect our intellectual property and the cost of
enforcing or defending our intellectual property rights; our failure to comply
with regulations relating to our products and product candidates, including FDA
requirements; the risk that the FDA may interpret the results of our studies
differently than we have; the risk that clinical trials may not result in
marketable products; the risk that we may be unable to successfully secure
regulatory approval of and market our drug candidates; risks of new, changing
and competitive technologies and regulations in the U.S. and internationally;
general worldwide economic conditions and related uncertainties; future
legislative, regulatory, or tax changes as well as other economic, business
and/or competitive factors; and the effect of exchange rate fluctuations on our
international operations. The list of risks above is not exhaustive. This press
release contains additional factors that could impact our businesses and
financial performance. We expressly disclaim any obligation or undertaking to
release publicly any updates or revisions to such statements to reflect any
change in our expectations or any change in events, conditions or circumstances
on which any such statement is based.


--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


PDF of Press Release:
http://hugin.info/131215/R/1507528/442428.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Evotec AG via Thomson Reuters ONE

[HUG#1507528]
Related Links: Evotec SE
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.